ERBB2 and gastric cancer: The novel secretable BiTE, αHER2/CD3, consists of HER2-specific scFv 4D5, CD3-specific scFv OKT3 and flexible linkers can specifically target HER2+ tumor cells, such as those found in gastric cancer and CD3+ human T cells [207].